Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tarsus Pharmaceuticals (TARS) Revenue (2021 - 2025)

Tarsus Pharmaceuticals has reported Revenue over the past 5 years, most recently at $151.7 million for Q4 2025.

  • Quarterly results put Revenue at $151.7 million for Q4 2025, up 128.39% from a year ago — trailing twelve months through Dec 2025 was $451.4 million (up 146.71% YoY), and the annual figure for FY2025 was $451.4 million, up 146.71%.
  • Revenue for Q4 2025 was $151.7 million at Tarsus Pharmaceuticals, up from $118.7 million in the prior quarter.
  • Over the last five years, Revenue for TARS hit a ceiling of $151.7 million in Q4 2025 and a floor of $338000.0 in Q4 2021.
  • Median Revenue over the past 5 years was $24.8 million (2021), compared with a mean of $40.8 million.
  • Peak annual rise in Revenue hit 2858.58% in 2022, while the deepest fall reached 98.39% in 2022.
  • Tarsus Pharmaceuticals' Revenue stood at $338000.0 in 2021, then surged by 2858.58% to $10.0 million in 2022, then surged by 30.76% to $13.1 million in 2023, then surged by 407.86% to $66.4 million in 2024, then soared by 128.39% to $151.7 million in 2025.
  • The last three reported values for Revenue were $151.7 million (Q4 2025), $118.7 million (Q3 2025), and $102.7 million (Q2 2025) per Business Quant data.